Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab vs sham in macular edema secondary to CRVO
2006-005468-25Phase 3Completed
- Sponsor
- Retinaklinikken Omnia
- Start
- Dec 2006
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of ranibizumab in central retinal vein occlusion with macular edema and macular edema (2 arms), sponsored by Retinaklinikken Omnia. Primary endpoints: Visual acuity at 6 months and Macular thickness at 6 months. Started Dec 2006; status: completed.
02
Drugs
ranibizumab
03
Conditions
central retinal vein occlusion with macular edemamacular edema
Beyond the preview
Go deeper on 2006-005468-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005468-25.